• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Cell Therapeutics

Legend
Pharma

J&J, Legend pull ASH paper comparing Carvykti to rival CAR-T

The presentation was a comparison between anito-cel’s iMMagine-1 and Carvykti’s Cartitude-1 and -4 trials for the treatment of multiple myeloma. 
Angus Liu Nov 12, 2025 11:36am
Marks

FDA turmoil compounds challenges for cell and gene therapy field

Apr 2, 2025 3:16pm
Legend

J&J, Legend to invest $150M in Belgium cell therapy facility

Mar 12, 2025 2:15pm
graphic of a larger shark chomping up a smaller one

BMS buys cell therapy partner 2seventy bio for $286M

Mar 11, 2025 10:12am
BreyanziProductImageforMCL

BMS angles Breyanzi for another blood cancer

Feb 10, 2025 9:50am
Marks

FDA revisits CAR-T boxed warning on secondary cancers: Marks

Nov 1, 2024 10:30am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings